Redcliffe Labs appoints Kshitiz Singh as Chief Business Officer

Redcliffe Labs has announced the appointment of Kshitiz Singh as Chief Business Officer – Inorganic Growth, as the company strengthens its leadership team to drive the next phase of strategic expansion through acquisitions, partnerships and network integration.

The appointment reflects Redcliffe Labs' continued focus on building an integrated diagnostics ecosystem that combines pathology, radiology, technology, and preventive healthcare while expanding its presence across regional markets.

As Chief Business Officer – Inorganic Growth, Singh will lead the company's mergers and acquisitions strategy, strategic partnerships, and post-acquisition integration initiatives. Working closely with the leadership team, he will focus on identifying high-impact growth opportunities, integrating regional diagnostic businesses into Redcliffe Labs' operating platform, and strengthening the company's diagnostics network across India.

Singh joins Redcliffe Labs with more than 26 years of leadership experience across diagnostics, healthcare, pharmaceuticals, FMCG, sales leadership, business development and commercial strategy. Throughout his career, he has led large-scale business operations, expanded regional markets, built high-performing commercial teams, and delivered sustainable business growth across multiple organisations.

Before joining Redcliffe Labs, Singh served as General Manager and Business Head at Agilus Diagnostics, where he played a key role in driving business expansion and strengthening the company's market presence. Earlier, he held leadership positions at other national-level healthcare companies, Piramal Enterprises, Abbott India, Heinz India, Sanofi, AstraZeneca, and GlaxoSmithKline, gaining extensive experience in diagnostics, commercial strategy, business development, channel management, and organisational growth.